SUMMER 2017
Drug Discovery World
Tackling multi-drug resistant bacteria
By Dr Ankit Mahadevia

Antibiotic resistance never should have become the public health crisis we are seeing today. As a society, we thought the problem of bacterial infections had been solved decades ago when more than 200 powerful antibiotics representing different classes such as -lactam, tetracyclines and macrolides were developed.

Names such as amoxicillin, clindamycin and erythromycin have become well-known among consumers. Signs of resistance to antibiotics appeared almost immediately and continues to plague our healthcare systems.

The CDC estimates that every year, at least 2 million people are infected with drug resistant bacteria. Of these, 23,000 will die. The financial cost to the US is expected to range from $20 billion to $35 billion. On a global scale, the numbers are equally frightening. The World Health Organization estimates 700,000 people will die worldwide each year from multidrug resistant micro-organisms. Premature deaths could reach 10 million annually by 2050, according to the United Kingdom’s Review on Antimicrobial Resistance. That could cost the global gross domestic product (GDP) $100 trillion in economic productivity...

You just need to REGISTER - its FREE - to read the rest of this article straight away.